NIKKEI 225
38,073.98 -128.39 (-0.34%) HANG SENG
18,537.81 +223.95 (+1.22%) CRUDE OIL
79.51 +0.52 (+0.66%) GOLD FUTURES
2,344.50 +22.20 (+0.96%) DOW
39,390.00 +333.61 (+0.85%) Bitcoin GBP
49,748.40 +118.34 (+0.24%)
Astellas Pharma Inc. (ALPMF)
| Previous close | 10.03 |
| Open | 10.03 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 10.03 - 10.03 |
| 52-week range | 9.13 - 17.00 |
| Volume | |
| Avg. volume | 2,373 |
| Market cap | 17.994B |
| Beta (5Y monthly) | 0.31 |
| PE ratio (TTM) | 501.75 |
| EPS (TTM) | 0.02 |
| Earnings date | 30 Jul 2024 - 05 Aug 2024 |
| Forward dividend & yield | 0.48 (4.75%) |
| Ex-dividend date | 30 Sept 2024 |
| 1y target est | N/A |
PR NewswireAstellas Unveils New, State-of-the-Art, $90 Million West Coast Innovation Center in the South San Francisco Biotech Corridor
Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced the opening of a new $90 million, state-of-the-art center at 480 Forbes Boulevard in South San Francisco, CA. The newly built 154,000-square-foot lab and office facility expands the company's commitment to South San Francisco's biotech ecosystem and creates a central location for its West Coast employees across Research, Technical Operations, Medical and Development and Commercial, previously located i
PR NewswireAstellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in Oncology
Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and Poseida Therapeutics, Inc. (NASDAQ: PSTX, President and CEO: Kristin Yarema, "Poseida") today announced that Xyphos Biosciences, Inc., (a wholly owned subsidiary of Astellas, "Xyphos") and Poseida have entered into a research collaboration and license agreement to develop novel convertibleCAR® programs by combining the innovative cell therapy platforms from each of the companies.
- PR Newswire
Astellas' XTANDI™ (Enzalutamide) Granted European Commission Approval for Use in Additional Recurrent Early Prostate Cancer Treatment Setting
Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced the European Commission (EC) has approved a label extension for XTANDI™ (enzalutamide) as monotherapy or in combination with androgen deprivation therapy (ADT) for the treatment of adult men with high-risk biochemical recurrent (BCR) non-metastatic hormone-sensitive prostate cancer (nmHSPC) who are unsuitable for salvage-radiotherapy.
